2025 Poster Presentations
P315: RESPONSIVENESS OF GLOMANGIOPERICYTOMA TO INDUCTION CHEMOTHERAPY
Hannah Casteel, BA; Alexander Sokohl, MD; Peter Hunt, MD; Justin Morse, MD; Associates in ENT
Background: Glomangiopericytoma (GPC) is a rare malignant tumor arising from pericytes in the nasal cavity or paranasal sinuses. Standard treatment is margin negative surgical excision without the use of chemotherapy or radiation. We present a case of GPC treated with induction chemotherapy due to a second primary malignancy with delayed secondary surgery.
Objectives: To report the response of GPC to initial treatment with chemotherapy in a patient with simultaneous oropharyngeal squamous cell carcinoma (SCC) and GPC.
Case Report: A 57-year-old male presented with a right base of tongue mass. Imaging revealed a secondary mass in the posterior right nasal cavity. Biopsy and staging of the base of tongue lesion confirmed SCC (T3 N1 M0) and GPC of the posterior right septum and olfactory cleft. Treatment was initiated for the primary SCC, with surveillance of the GPC. Following completion of chemoradiation therapy, repeat imaging and endoscopy confirmed a favorable response to systemic chemotherapy with size reduction in the known GPC. Subsequently, the patient underwent staged right endoscopic craniofacial resection of the GPC. At 12 months out from treatment patient remains disease free from both oropharyngeal and sinonasal malignancy.
Results: GPC demonstrates a favorable treatment response to systemic chemotherapy and can be safely monitored while patient is undergoing treatment for second primary malignancy.
Conclusion: This case demonstrates GPC has a favorable response to systemic chemotherapy. These results suggest induction chemotherapy may be beneficial for GPC considered unresectable.